Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VIAGENE HIV-IT(V) PHASE II GENE THERAPY TRIAL

Executive Summary

VIAGENE HIV-IT(V) PHASE II GENE THERAPY TRIAL is under way with an enrollment target of 190 patients at up to 15 centers nationwide, San Diego-based Viagene announced Dec. 5. The placebo- controlled, triple-blinded study, which is being funded by the Green Cross Corp. of Japan, employs Viagene's injectable HIV immunotherapeutic vector designed to deliver the HIV env and rev genes to non-HIV infected cells in order to stimulate a cytotoxic T-lymphocyte response. The study "is the largest and the most clinically advanced gene transfer study ever to be initiated," Viagene noted.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel